Literature DB >> 25392014

Molecular pathophysiology of priapism: emerging targets.

Uzoma A Anele, Belinda F Morrison, Arthur L Burnett1.   

Abstract

Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25392014      PMCID: PMC4430197          DOI: 10.2174/1389450115666141111111842

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  121 in total

Review 1.  Cyclic GMP phosphodiesterase-5: target of sildenafil.

Authors:  J D Corbin; S H Francis
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

2.  Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation.

Authors:  Phillip M Pierorazio; Trinity J Bivalacqua; Arthur L Burnett
Journal:  J Androl       Date:  2010-12-02

3.  Priapism in teenage boys following depot testosterone.

Authors:  James F Donaldson; Nikki Davis; Justin H Davies; Roland W Rees; Henrik A Steinbrecher
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

4.  Priapism, its incidence and seasonal distribution in Finland.

Authors:  R V Kulmala; T A Lehtonen; T L Tammela
Journal:  Scand J Urol Nephrol       Date:  1995-03

Review 5.  A pathophysiology-based approach to the management of early priapism.

Authors:  Jason R Kovac; Siu K Mak; Maurice M Garcia; Tom F Lue
Journal:  Asian J Androl       Date:  2012-12-03       Impact factor: 3.285

6.  Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.

Authors:  Annamaria Morelli; Sandra Filippi; Rosa Mancina; Michaela Luconi; Linda Vignozzi; Mirca Marini; Claudio Orlando; Gabriella Barbara Vannelli; Antonio Aversa; Alessandro Natali; Gianni Forti; Mauro Giorgi; Emmanuele A Jannini; Fabrizio Ledda; Mario Maggi
Journal:  Endocrinology       Date:  2004-02-05       Impact factor: 4.736

Review 7.  Life history of eNOS: partners and pathways.

Authors:  David M Dudzinski; Thomas Michel
Journal:  Cardiovasc Res       Date:  2007-04-03       Impact factor: 10.787

8.  Follow-up of sickle cell disease patients with priapism treated by hydroxyurea.

Authors:  Sara T O Saad; Camila Lajolo; Simone Gilli; José Francisco C Marques Júnior; Carmen S Lima; Fernando F Costa; Valder R Arruda
Journal:  Am J Hematol       Date:  2004-09       Impact factor: 10.047

9.  hSMR3A as a marker for patients with erectile dysfunction.

Authors:  Yuehong Tong; Moses Tar; Val Monrose; Michael DiSanto; Arnold Melman; Kelvin P Davies
Journal:  J Urol       Date:  2007-05-23       Impact factor: 7.450

10.  Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress.

Authors:  Trinity J Bivalacqua; Biljana Musicki; Lewis L Hsu; Dan E Berkowitz; Hunter C Champion; Arthur L Burnett
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  14 in total

1.  Nitrergic Mechanisms for Management of Recurrent Priapism.

Authors:  Uzoma A Anele; Arthur L Burnett
Journal:  Sex Med Rev       Date:  2015-06-04

2.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

3.  Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.

Authors:  B Musicki; S Karakus; W Akakpo; F H Silva; J Liu; H Chen; B R Zirkin; A L Burnett
Journal:  Andrology       Date:  2017-11-16       Impact factor: 3.842

4.  Priapism, hemoglobin desaturation, and red blood cell adhesion in men with sickle cell anemia.

Authors:  Charlotte Yuan; Erina Quinn; Erdem Kucukal; Sargam Kapoor; Umut A Gurkan; Jane A Little
Journal:  Blood Cells Mol Dis       Date:  2019-08-05       Impact factor: 3.039

Review 5.  Review of Ischemic and Non-ischemic Priapism.

Authors:  Mark G Biebel; Martin S Gross; Ricardo Munarriz
Journal:  Curr Urol Rep       Date:  2022-05-10       Impact factor: 3.092

Review 6.  What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.

Authors:  S Minhas; A Salonia; M Gül; B Luca; K Dimitropoulos; P Capogrosso; U Milenkovic; A Cocci; R Veeratterapillay; G Hatzichristodoulou; V Modgil; G I Russo; T Tharakan; A Kalkanli; M I Omar; C Bettocchi; J Carvalho; G Corona; T H Jones; A Kadioglu; J I Martinez-Salamanca; E C Serefoglu; P Verze
Journal:  Int J Impot Res       Date:  2022-08-08       Impact factor: 2.408

Review 7.  Management of refractory ischemic priapism: current perspectives.

Authors:  Marco Capece; Arianna Gillo; Andrea Cocci; Giulio Garaffa; Massimiliano Timpano; Marco Falcone
Journal:  Res Rep Urol       Date:  2017-08-29

Review 8.  Neuroprotective and Nerve Regenerative Approaches for Treatment of Erectile Dysfunction after Cavernous Nerve Injury.

Authors:  Jeffrey D Campbell; Arthur L Burnett
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

9.  Prevalence of priapism in individuals with sickle cell disease and implications on male sexual function.

Authors:  Mateus Andrade Alvaia; Heros Aureliano Antunes da Silva Maia; Alana de Medeiros Nelli; Carina Oliveira Silva Guimarães; Evanilda Souza de Santana Carvalho; José Murillo Bastos Netto; Eduardo de Paula Miranda; Cristiano Mendes Gomes; José de Bessa Júnior
Journal:  Einstein (Sao Paulo)       Date:  2020-04-22

10.  Risk Factors for Surgical Shunting in a Large Cohort With Ischemic Priapism.

Authors:  Hanson Zhao; Kai Dallas; John Masterson; Eric Lo; Justin Houman; Carl Berdahl; Joshua Pevnick; Jennifer T Anger
Journal:  J Sex Med       Date:  2020-11-15       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.